These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38976762)

  • 1. Ultra-low-dose continuous combined estradiol and dydrogesterone in postmenopausal women: A pooled safety and tolerability analysis.
    Tatarchuk T; Stevenson JC; Yu Q; Kahler E; Graziano Custodio M; Ren M; Nappi RE; Karpova V; Simoncini T
    Gynecol Endocrinol; 2024 Dec; 40(1):2375577. PubMed ID: 38976762
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultra-low-dose estradiol and dydrogesterone for treatment of vasomotor symptoms in Europe and China.
    Yu Q; Stevenson JC; Tatarchuk T; Nappi RE; Graziano Custodio M; Kahler E; Simoncini T; Yang J; Ren M
    Climacteric; 2024 Oct; 27(5):494-500. PubMed ID: 39077780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral ultra-low dose continuous combined hormone replacement therapy with 0.5 mg 17β-oestradiol and 2.5 mg dydrogesterone for the treatment of vasomotor symptoms: results from a double-blind, controlled study.
    Stevenson JC; Durand G; Kahler E; Pertyński T
    Maturitas; 2010 Nov; 67(3):227-32. PubMed ID: 20688442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone.
    Ferenczy A; Gelfand MM; van de Weijer PH; Rioux JE
    Climacteric; 2002 Mar; 5(1):26-35. PubMed ID: 11974556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone.
    Lees B; Stevenson JC
    Osteoporos Int; 2001; 12(4):251-8. PubMed ID: 11420773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol.
    Burch DJ; Spowart KJ; Jesinger DK; Randall S; Smith SK
    Br J Obstet Gynaecol; 1995 Mar; 102(3):243-8. PubMed ID: 7794851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China.
    Ren M; Ruan X; Gu L; Pexman-Fieth C; Kahler E; Yu Q
    Climacteric; 2022 Jun; 25(3):286-292. PubMed ID: 34402360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of a low-dose continuous combined hormone replacement therapy with 0.5 mg 17β-estradiol and 2.5 mg dydrogesterone in subgroups of postmenopausal women with vasomotor symptoms.
    Tsiligiannis S; Wick-Urban BC; van der Stam J; Stevenson JC
    Maturitas; 2020 Sep; 139():20-26. PubMed ID: 32747036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transdermal estradiol gel for the treatment of symptomatic postmenopausal women.
    Archer DF; Pickar JH; MacAllister DC; Warren MP
    Menopause; 2012 Jun; 19(6):622-9. PubMed ID: 22282101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.
    Samsioe G; Hruska J;
    Climacteric; 2010 Feb; 13(1):34-44. PubMed ID: 20001563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bleeding patterns and endometrial histology during administration of low-dose estradiol sequentially combined with dydrogesterone.
    van de Weijer PH; Scholten PC; van der Mooren MJ; Barentsen R; Kenemans P
    Climacteric; 1999 Jun; 2(2):101-9. PubMed ID: 11910662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra low dose continuous combined hormone replacement therapy with 0.5mg 17beta-oestradiol and 2.5mg dydrogesterone: protection of the endometrium and amenorrhoea rate.
    Bergeron C; Nogales FF; Rechberger T; Tatarchjuk T; Zipfel L
    Maturitas; 2010 Jun; 66(2):201-5. PubMed ID: 20378287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individual effect of E2 and dydrogesterone on insulin sensitivity in post-menopausal women.
    Soranna L; Cucinelli F; Perri C; Muzj G; Giuliani M; Villa P; Lanzone A
    J Endocrinol Invest; 2002 Jun; 25(6):547-50. PubMed ID: 12109627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of ultralow-dose transdermal estradiol on postmenopausal symptoms in women aged 60 to 80 years.
    Diem S; Grady D; Quan J; Vittinghoff E; Wallace R; Hanes V; Ensrud K
    Menopause; 2006; 13(1):130-8. PubMed ID: 16607109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women.
    Lin SQ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Zhou YZ; Wang ML; Zhu J; Chen SR; Su H; Yang CS; Wang SH; Zhang YZ; Dong XJ
    Climacteric; 2011 Aug; 14(4):472-81. PubMed ID: 21469973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ultra-low-dose estradiol and dydrogesterone on arterial stiffness in postmenopausal women.
    Matsui S; Yasui T; Tani A; Kato T; Uemura H; Kuwahara A; Matsuzaki T; Arisawa K; Irahara M
    Climacteric; 2014 Apr; 17(2):191-6. PubMed ID: 24164272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the contribution of dydrogesterone to bone turnover changes in postmenopausal women commencing hormone replacement therapy.
    Tobias JH; Clarke S; Mitchell K; Robins S; Amer H; Fraser WD
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1194-8. PubMed ID: 11238508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of low-dose 17beta-estradiol plus dydrogesterone on 24-h ambulatory blood pressure in healthy postmenopausal women: a 1-year, randomized, prospective study.
    Kaya C; Cengiz SD; Cengiz B; Akgun G
    Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():62-7. PubMed ID: 17943541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.